Literature DB >> 7520838

Oral tolerance to myelin basic protein induces regulatory TGF-beta-secreting T cells in Peyer's patches of SJL mice.

L M Santos1, A al-Sabbagh, A Londono, H L Weiner.   

Abstract

Oral administration of myelin basic protein (MBP) is an effective means of suppressing experimental autoimmune encephalomyelitis (EAE). In the Lewis rat model, we have previously shown that this effect is mediated by active suppression as T lymphocytes from animals orally tolerized to MBP suppress in vitro immune responses and in vivo adoptively transfer disease protection to naive recipients. This effect is mediated by the cytokine TGF-beta which is secreted by T cells from orally tolerized animals after being triggered by the oral tolerogen. In the present study we investigated Peyer's patches in SJL mice following orally administered MBP. Peyer's patches are one of the major lymphoid structures of gut-associated lymphoid tissue, and a site thought to play an important role in the induction of oral tolerance. Twenty-four hours after one feeding of 1 mg of MBP, there were no proliferative responses to MBP in Peyer's patches. However, when Peyer's patches from MBP-fed animals were stimulated with IL-2 in the presence of MBP, reduced proliferation to IL-2 was observed, and this inhibition was reversed with anti-TGF-beta antibody. Suppression of IL-2-induced proliferation by MBP was not observed in unfed animals or if Peyer's patches from MBP-fed animals were stimulated with a control antigen (ovalbumin). Stimulation of Peyer's patches T cells from MBP-fed animals with MBP resulted in secretion of TGF-beta in a dose-related fashion with less TGF-beta secretion at higher doses. Furthermore, cells from Peyer's patches of animals fed MBP adoptively transferred protection to actively induced EAE. Thus, MBP-specific TGF-beta-secreting regulatory cells recovered from Peyer's patches after a single oral administration of MBP are not evident as measured by proliferation, but are capable of suppressing in vitro and in vivo cell-mediated immune responses. Peyer's patches appear to be an important site for the induction of cells which mediate the active suppression component of oral tolerance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7520838     DOI: 10.1006/cimm.1994.1240

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  19 in total

1.  Enhanced mucosal and systemic immune responses to intestinal reovirus infection in beta2-microglobulin-deficient mice.

Authors:  A S Major; C F Cuff
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Coaxing the liver into preventing autoimmune disease in the brain.

Authors:  Brad E Hoffman; Roland W Herzog
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

Review 3.  Oral tolerance and the treatment of rheumatoid arthritis.

Authors:  H L Weiner; Y Komagata
Journal:  Springer Semin Immunopathol       Date:  1998

Review 4.  Oral tolerance.

Authors:  H L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

5.  Total dose and frequency of administration critically affect success of nasal mucosal tolerance induction.

Authors:  H R Jiang; N Taylor; L Duncan; A D Dick; J V Forrester
Journal:  Br J Ophthalmol       Date:  2001-06       Impact factor: 4.638

6.  Immunologic tolerance to myelin basic protein decreases stroke size after transient focal cerebral ischemia.

Authors:  K J Becker; R M McCarron; C Ruetzler; O Laban; E Sternberg; K C Flanders; J M Hallenbeck
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-30       Impact factor: 11.205

7.  Breakdown of mucosal immunity in gut by 2,3,7,8-tetraclorodibenzo-p-dioxin (TCDD).

Authors:  Hirokazu Kinoshita; Jun Abe; Kenji Akadegawa; Hideaki Yurino; Tetsuya Uchida; Shigaku Ikeda; Kouji Matsushima; Sho Ishikawa
Journal:  Environ Health Prev Med       Date:  2006-09       Impact factor: 3.674

8.  The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes.

Authors:  M Paas-Rozner; M Sela; E Mozes
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

9.  Oral administration of type II collagen suppresses pro-inflammatory mediator production by synoviocytes in rats with adjuvant arthritis.

Authors:  C H Ding; Q Li; Z Y Xiong; A W Zhou; G Jones; S Y Xu
Journal:  Clin Exp Immunol       Date:  2003-06       Impact factor: 4.330

10.  Gene therapy in allergic encephalomyelitis using myelin basic protein-specific T cells engineered to express latent transforming growth factor-beta1.

Authors:  L Z Chen; G M Hochwald; C Huang; G Dakin; H Tao; C Cheng; W J Simmons; G Dranoff; G J Thorbecke
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.